M
MyoKardia
Develops novel, small molecule therapeutics that address key clinical needs of patients with genetic heart diseases
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- CGCowen Group
Casdin Capital- SASanofi
BridgeBio
Cormorant Asset Management
Third Rock Ventures
Series B and later4 investors entered at this stage
- UBUniversity of Colorado Boulder
- SUStanford University
- HUHarvard University
- HSHarvard Medical School
Source: Dealroom Talent Intelligence.
Alumni founders
Former MyoKardia employees who went on to found companies, sorted by Dealroom signal score.
Jay EdelbergUnited StatesBRBridgeBioEst. 2014
Neil KumarUnited States
June LeeUnited States
Priyanka Agarwal, MD, MBAUnited States
MTMaze TherapeuticsEst. 2018
Eric GreenUnited StatesGlobal footprint
team presence
Patents
31 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about MyoKardia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MyoKardia on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.